Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FULC NASDAQ:IVA NASDAQ:NBTX NASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$6.64-2.6%$7.13$2.32▼$9.90$359.16M2.47588,321 shs475,521 shsIVAInventiva$4.59+5.3%$3.35$1.53▼$4.64$439.08M0.7317,699 shs39,718 shsNBTXNanobiotix$8.80+11.3%$5.70$2.76▼$8.96$421.87M0.4511,310 shs13,564 shsQNCXQuince Therapeutics$1.67-1.2%$1.61$0.54▼$2.45$89.70M1.02237,856 shs81,468 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics0.00%+5.08%-10.85%-1.59%-26.19%IVAInventiva0.00%+21.79%+32.68%+38.41%+98.18%NBTXNanobiotix0.00%+7.18%+50.38%+100.76%+59.80%QNCXQuince Therapeutics0.00%+2.42%-10.58%+77.89%+208.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFULCFulcrum Therapeutics1.353 of 5 stars3.31.00.00.01.31.70.0IVAInventiva3.588 of 5 stars3.45.00.00.04.11.70.6NBTXNanobiotix0.8158 of 5 stars1.33.00.00.03.30.00.6QNCXQuince Therapeutics2.629 of 5 stars3.73.00.00.02.40.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFULCFulcrum Therapeutics 2.63Moderate Buy$7.5714.03% UpsideIVAInventiva 2.80Moderate Buy$10.40126.58% UpsideNBTXNanobiotix 2.50Moderate Buy$8.00-9.09% DownsideQNCXQuince Therapeutics 3.30Buy$8.14387.60% UpsideCurrent Analyst Ratings BreakdownLatest QNCX, NBTX, FULC, and IVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.008/12/2025QNCXQuince TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$9.00 ➝ $8.008/5/2025QNCXQuince TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform8/5/2025QNCXQuince TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$9.008/5/2025QNCXQuince TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$9.007/30/2025FULCFulcrum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $5.007/29/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $12.007/17/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/13/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/4/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/29/2025FULCFulcrum TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$6.00 ➝ $9.00(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFULCFulcrum Therapeutics$80M4.49N/AN/A$4.51 per share1.47IVAInventiva$9.95M44.13N/AN/A($1.21) per share-3.79NBTXNanobiotix$39.18M10.77N/AN/A($1.51) per share-5.83QNCXQuince TherapeuticsN/AN/AN/AN/A$0.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFULCFulcrum Therapeutics-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%N/AIVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)QNCXQuince Therapeutics-$56.83M-$1.09N/AN/AN/AN/A-187.49%-42.47%N/ALatest QNCX, NBTX, FULC, and IVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025QNCXQuince Therapeutics-$0.28-$0.34-$0.06-$0.34N/AN/A7/29/2025Q2 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFULCFulcrum TherapeuticsN/A24.4224.42IVAInventivaN/A0.920.92NBTXNanobiotixN/A1.041.04QNCXQuince Therapeutics1.455.005.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFULCFulcrum Therapeutics89.83%IVAInventiva19.06%NBTXNanobiotix38.81%QNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipFULCFulcrum Therapeutics7.00%IVAInventiva32.00%NBTXNanobiotix3.45%QNCXQuince Therapeutics16.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFULCFulcrum Therapeutics10054.09 million50.31 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableNBTXNanobiotix10047.94 million46.29 millionNot OptionableQNCXQuince Therapeutics6053.71 million44.69 millionOptionableQNCX, NBTX, FULC, and IVA HeadlinesRecent News About These CompaniesQuince Therapeutics (NASDAQ:QNCX) Receives Buy Rating from D. Boral CapitalAugust 18 at 2:01 AM | americanbankingnews.comQNCX Q3 EPS Estimate Lifted by Brookline Capital ManagementAugust 17 at 8:58 AM | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Receives "Buy" Rating from D. Boral CapitalAugust 17 at 8:29 AM | marketbeat.comQNCX FY2029 EPS Increased by Brookline Capital ManagementAugust 16 at 11:29 AM | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 16 at 4:57 AM | marketbeat.comQNCX Q3 EPS Estimate Raised by Brookline Capital ManagementAugust 16 at 2:45 AM | americanbankingnews.comJMP Securities Cuts Quince Therapeutics (NASDAQ:QNCX) Price Target to $8.00August 14, 2025 | americanbankingnews.comQuince Therapeutics (NASDAQ:QNCX) Price Target Cut to $8.00 by Analysts at JMP SecuritiesAugust 13, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPSAugust 12, 2025 | marketbeat.comQuince Therapeutics price target lowered to $8 from $9 at Citizens JMPAugust 12, 2025 | msn.comQuince Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comQuince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | businesswire.comQuince Therapeutics (QNCX) Expected to Announce Quarterly Earnings on TuesdayAugust 11, 2025 | americanbankingnews.comQuince Therapeutics (QNCX) Projected to Post Earnings on TuesdayAugust 6, 2025 | marketbeat.comJMP Securities Begins Coverage on Quince Therapeutics (NASDAQ:QNCX)August 6, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Citizens JmpAugust 6, 2025 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Up 64.5% in JulyAugust 6, 2025 | marketbeat.comJMP Securities Initiates Coverage of Quince Therapeutics (QNCX) with Market Outperform RecommendationAugust 5, 2025 | msn.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of "Buy" by AnalystsJuly 21, 2025 | marketbeat.comBrookline Capital Management Comments on QNCX Q3 EarningsJuly 21, 2025 | marketbeat.comQuince Therapeutics, Inc. (QNCX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNCX, NBTX, FULC, and IVA Company DescriptionsFulcrum Therapeutics NASDAQ:FULC$6.64 -0.18 (-2.64%) Closing price 04:00 PM EasternExtended Trading$6.64 +0.00 (+0.08%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Inventiva NASDAQ:IVA$4.46 +0.10 (+2.18%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Nanobiotix NASDAQ:NBTX$8.80 +0.89 (+11.25%) Closing price 03:59 PM EasternExtended Trading$8.75 -0.05 (-0.57%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Quince Therapeutics NASDAQ:QNCX$1.67 -0.02 (-1.18%) Closing price 04:00 PM EasternExtended Trading$1.68 +0.02 (+0.90%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Whirlpool A Screamin’ Buy in 2025? Signs Say Yes Rocket Stock Just Broke Out, But EPS Growth Still Isn't Priced In Buffett Makes Big Moves Outside of UNH: A Buy and Sell Breakdown Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Why Arista's Blowout Q2 Is Good News for Chip-Giant Broadcom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.